Under construction – not a live service
Sign in
Taking people in DenmarkNo phase

Blood tests to tell cancerous from harmless lung nodules

Studies blood markers to help judge whether a lung nodule is cancer.

Plain-language title generated from the registry record
Registry title: Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation

Key facts

Where
Gentofte Municipality, DenmarkSee the site

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with a newly found lung nodule that may be lung cancer and who were sent to the infiltrate unit. Blood tests will be studied to tell cancerous from non-cancerous nodules.

Sex
All sexes can join.
Disease stage
A newly detected lung nodule (IPN) suspected of lung cancer.

Main reasons for not taking part

  • Active cancer, other than non-melanoma skin cancer
  • Other illnesses that make clinical follow-up and a final diagnosis impossible

Read by machine on 9 November 2026.

Where in Denmark

  • Gentofte HospitalGentofte Municipality, DenmarkTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Herlev and Gentofte Hospital
Trial code
NCT07623473
Record updated
3 June 2026
Original description
The goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule.Read full original descriptionShow less

NIMBLE | Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation

The goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule.

Each blood biomarker will be evaluated for descriminating malignant from benign lung nodules alone and in combination with other blood biomarkers, patient characteristics and radiological features.

Inclusion: Patients with a newly detected IPN suspected of lung cancer referred to the infiltrate unit; Having signed informed consent.

Exclusion: Active cancer, excluding non-melanoma skin cancer; Comorbidities that exclude the patient from clinical follow-up and final diagnosis.

ClinicalTrials.gov NCT07623473